JP5103179B2 - スタチンおよびオメガ−3脂肪酸を含む組成物 - Google Patents
スタチンおよびオメガ−3脂肪酸を含む組成物 Download PDFInfo
- Publication number
- JP5103179B2 JP5103179B2 JP2007524466A JP2007524466A JP5103179B2 JP 5103179 B2 JP5103179 B2 JP 5103179B2 JP 2007524466 A JP2007524466 A JP 2007524466A JP 2007524466 A JP2007524466 A JP 2007524466A JP 5103179 B2 JP5103179 B2 JP 5103179B2
- Authority
- JP
- Japan
- Prior art keywords
- day
- omega
- diabetes
- cis
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
このたび驚くべきことに、特定の薬理作用について知られている特定の物質の組合せが、インスリン抵抗性、およびそれに関連する病的側面ならびに心血管疾患の治療に特に望ましいことが見いだされた。
本発明による組合せは、医薬分野において知られており、既に臨床治療で用いられている活性成分から実質的になる。それゆえ、それらは、これまでかなりの期間市場に出回っており、ヒトまたは動物投与に好適な質である物質であるため、入手するのは非常に容易である。
シンバスタチン; 10 mg 〜 40 mg/日、好ましくは 10 mg/日;
コエンザイム Q10: 5 mg 〜 50 mg/日、好ましくは 10 mg/日;
リスベラトロール: 1 mg 〜 5 mg/日、好ましくは 2.5 mg/日;
ポリコサノール: ヘキサコサノール: 5 mg 〜 15 mg/日、好ましくは 10 mg/日;
パンテチン: 10 mg 〜 30 mg/日、好ましくは 20 mg/日;
セレン: 25 μg〜75 μg/日、好ましくは 50 μg/日;
亜鉛: 5 mg 〜 15 mg/日、好ましくは10 mg/日。
db/db マウスにおける抗糖尿病活性および血清脂質低下活性
実験動物における突然変異により、肥満、高脂血症およびインスリン抵抗性を伴う非インスリン依存性糖尿病を提示するモデルの開発が可能となり、それによって本発明者らは、新規抗糖尿病性化合物の有効性の試験をすることが可能となった(Reed and Scribner、Diabetes、Obesity and metabolism 1: 75 - 86、1999)。
オメガ-3 脂肪酸 (EPA +DHA 1:1) 200 mg/kg;
シンバスタチン 100 mg/kg;
オメガ-3 脂肪酸 (200 mg/kg) + シンバスタチン (100 mg/kg);
オメガ-3 脂肪酸 (200 mg/kg) + シンバスタチン (100 mg/kg); コエンザイム Q10 (50 mg/kg) + リスベラトロール (5 mg/kg) + ポリコサノール (ヘキサコサノール 25 mg/kg) + パンテチン (100 mg/kg) + セレン (0.5 μg/kg) + 亜鉛 (2.5 mg/kg)。
表に示す化合物および用量で1日2回経口的に12日間処置されたdb/db マウスの血液 グルコースレベル
摂食条件で、最後の処置後およそ 15 時間におけるサンプル
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で1日2回経口的に12日間処置されたdb/db マウスの血液 グルコースレベル
吸収後条件 (絶食午前9時から午後5時)で、最後の処置の8 時間後におけるサンプル
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で18日間経口的に1日2回処置されたdb/db マウスの血液グルコースレベル
18 時間絶食し、最後の処置後5 時間のマウスにおけるサンプル
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で18日間経口的に1日2回処置されたdb/db マウスの血液におけるOGTTの曲線下面積 (AUC)
18 時間絶食し、最後の処置の5 時間後のマウスにおけるOGTT 試験 (グルコース 3 g/kg)
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で経口的に25 日間1日2回処置されたdb/db マウスの血漿フルクトサミンレベル
吸収後条件 (絶食午前9時から午後4時30分)で、最後の処置の7時間30分後におけるサンプル
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で経口的に25 日間1日2回処置されたdb/db マウスの血漿トリグリセリドレベル
吸収後条件 (絶食午前9時から午後4時30分)で、最後の処置の7時間30分後におけるサンプル
平均値±S.E. および対照に対する変異(%)
表に示す化合物および用量で経口的に25 日間1日2回処置されたdb/db マウスの血漿 HDL-コレステロールレベル
吸収後条件 (絶食 午前9時から午後4時30分)で最後の処置の7時間30分後におけるサンプル
平均値±S.E.および対照に対する変異(%)
Claims (4)
- 活性成分が以下:
a. シス 5,8,11,14,17-エイコサペンタエン酸 (EPA) およびシス 4,7,10,13,16,19-ドコサヘキサエン酸 (DHA)、およびそれらの医薬上許容される塩のいずれかからなる群から選択される、オメガ-3 脂肪酸: 500 mg 〜 2 g/日;
b.シンバスタチン: 10 mg 〜 40 mg/日;
c.コエンザイム Q10:5 mg 〜 50 mg/日;
d.リスベラトロール: 1 mg 〜 5 mg/日;
e.ポリコサノール: ヘキサコサノール: 5 mg 〜 15 mg/日;
f.パンテチン: 10 mg 〜 30 mg/日;
g.セレン: 25 μg〜 75 μg/日;
h.亜鉛: 5 mg 〜 15 mg/日;
のみからなる、2型糖尿病およびインスリン抵抗性の治療のための経口投与用医薬組成物。 - さらに少なくとも1つの医薬上許容される媒体または賦形剤を含む、請求項1の医薬組成物。
- シス 5,8,11,14,17-エイコサペンタエン酸(EPA)、および、シス 4,7,10,13,16,19-ドコサヘキサエン酸 (DHA)が、1:1の比で存在する、請求項 1または2の医薬組成物。
- 単位形態にて、または協調的に逐次形態にて投与するための、請求項1〜3のいずれかの医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2004A000395 | 2004-08-03 | ||
IT000395A ITRM20040395A1 (it) | 2004-08-03 | 2004-08-03 | Composizione comprendente statine e acidi grassi omega 3. |
PCT/IT2005/000414 WO2006013602A1 (en) | 2004-08-03 | 2005-07-19 | Composition containing statins and omega-3 fatty acids |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008509132A JP2008509132A (ja) | 2008-03-27 |
JP2008509132A5 JP2008509132A5 (ja) | 2008-09-04 |
JP5103179B2 true JP5103179B2 (ja) | 2012-12-19 |
Family
ID=35124288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007524466A Expired - Fee Related JP5103179B2 (ja) | 2004-08-03 | 2005-07-19 | スタチンおよびオメガ−3脂肪酸を含む組成物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8853229B2 (ja) |
EP (1) | EP1773312B1 (ja) |
JP (1) | JP5103179B2 (ja) |
KR (1) | KR101355122B1 (ja) |
CN (1) | CN1993119B (ja) |
AU (1) | AU2005268402B2 (ja) |
BR (1) | BRPI0514026A (ja) |
CA (1) | CA2573000C (ja) |
CY (1) | CY1115416T1 (ja) |
DK (1) | DK1773312T3 (ja) |
EA (1) | EA014444B1 (ja) |
ES (1) | ES2481169T3 (ja) |
HK (1) | HK1105871A1 (ja) |
IL (1) | IL180602A (ja) |
IT (1) | ITRM20040395A1 (ja) |
MX (1) | MX2007001009A (ja) |
NZ (1) | NZ552396A (ja) |
PL (1) | PL1773312T3 (ja) |
PT (1) | PT1773312E (ja) |
SI (1) | SI1773312T1 (ja) |
WO (1) | WO2006013602A1 (ja) |
ZA (1) | ZA200701816B (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1786414A4 (en) | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
DE102004063638A1 (de) * | 2004-12-31 | 2006-07-13 | Biosyn Arzneimittel Gmbh | Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen |
BRPI0607569A2 (pt) * | 2005-03-08 | 2009-09-15 | Reliant Pharmaceuticals Inc | composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária |
CN101365431A (zh) * | 2005-10-14 | 2009-02-11 | 帝斯曼知识产权资产管理有限公司 | 包含白藜芦醇的营养药物组合物的新颖用途 |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
US20080085911A1 (en) | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
DK2440065T3 (en) * | 2009-06-12 | 2018-12-10 | Calanus As | COPYPOD OIL COMPOSITION, FORMULATIONS CONTAINING THE OIL COMPOSITION, AND ITS APPLICATION FOR REDUCING VISCAL FAT COLLECTION, IMPROVEMENT OF GLUCOSET TOLERANCE AND PREVENTION OR TREATMENT OF PATIENTS |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) * | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
SG10201408508YA (en) | 2009-12-23 | 2015-02-27 | Defiante Farmacêutica S A | Combination composition useful for treating cardiovascular diseases |
US8557236B2 (en) * | 2010-02-09 | 2013-10-15 | Vascure Natural LLC | Cardiovascular support supplement and compositions and methods thereof |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012087487A1 (en) | 2010-12-20 | 2012-06-28 | Hill's Pet Nutrition, Inc. | Pet food compositions for inducing a satiety response |
AU2015201809B2 (en) * | 2010-12-20 | 2016-09-29 | Hill's Pet Nutrition, Inc. | Pet food compositions for inducing a satiety response |
KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물 |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
MY189576A (en) * | 2012-03-30 | 2022-02-17 | Micelle Biopharma Inc | Omega-3 fatty acid ester compositions |
US9682093B2 (en) | 2012-03-30 | 2017-06-20 | Charles R. Drew University Of Medicine And Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
WO2015003246A1 (en) * | 2013-07-09 | 2015-01-15 | Mcmaster University | Combination of a statin with an inflammasome inhibitor |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
RU2554806C1 (ru) * | 2014-07-29 | 2015-06-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа |
CN104922160A (zh) * | 2015-05-22 | 2015-09-23 | 舟山三合生物科技有限公司 | 他汀与Omega-3脂肪酸和辅酶Q10复配的组合物及其应用 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
ITUA20162575A1 (it) | 2016-04-13 | 2017-10-13 | S&R Farm S P A | Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1055638C (zh) | 1995-07-14 | 2000-08-23 | 李江 | 富硒虫草口服液及其制备方法 |
IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
US20030228393A1 (en) * | 2002-05-31 | 2003-12-11 | Zhao Iris Ginron | Multi-phase food & beverage |
CN1061259C (zh) * | 1998-11-24 | 2001-01-31 | 彭素萍 | 藜蒿中生物活性物质的富集物及用途 |
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
US20050002992A1 (en) * | 2003-06-17 | 2005-01-06 | Mccleary Edward Larry | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
US20020182585A1 (en) * | 2001-01-10 | 2002-12-05 | George Kindness | Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy |
US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US20040018248A1 (en) * | 2001-11-29 | 2004-01-29 | Adrianne Bendich | Composition containing statins and calcium for improved cardiovascular health |
US6855353B2 (en) * | 2002-03-08 | 2005-02-15 | Yaguang Liu | Method for producing antioxidant and prevention of cancer |
AU2003266287A1 (en) * | 2002-08-23 | 2004-03-11 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
WO2004028469A2 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Docohexaenoic acid for improved glycemic control |
CN1694695A (zh) * | 2002-11-07 | 2005-11-09 | 帝斯曼知识产权资产管理有限公司 | 包含表没食子儿茶素没食子酸酯的新颖的营养药物性组合物 |
-
2004
- 2004-08-03 IT IT000395A patent/ITRM20040395A1/it unknown
-
2005
- 2005-07-19 CA CA2573000A patent/CA2573000C/en not_active Expired - Fee Related
- 2005-07-19 PL PL05769486T patent/PL1773312T3/pl unknown
- 2005-07-19 MX MX2007001009A patent/MX2007001009A/es active IP Right Grant
- 2005-07-19 AU AU2005268402A patent/AU2005268402B2/en not_active Ceased
- 2005-07-19 US US11/632,953 patent/US8853229B2/en not_active Expired - Fee Related
- 2005-07-19 JP JP2007524466A patent/JP5103179B2/ja not_active Expired - Fee Related
- 2005-07-19 EA EA200700240A patent/EA014444B1/ru not_active IP Right Cessation
- 2005-07-19 SI SI200531865T patent/SI1773312T1/sl unknown
- 2005-07-19 ES ES05769486.1T patent/ES2481169T3/es active Active
- 2005-07-19 PT PT57694861T patent/PT1773312E/pt unknown
- 2005-07-19 NZ NZ552396A patent/NZ552396A/en not_active IP Right Cessation
- 2005-07-19 CN CN2005800258385A patent/CN1993119B/zh not_active Expired - Fee Related
- 2005-07-19 KR KR1020077004538A patent/KR101355122B1/ko not_active IP Right Cessation
- 2005-07-19 WO PCT/IT2005/000414 patent/WO2006013602A1/en active Application Filing
- 2005-07-19 DK DK05769486.1T patent/DK1773312T3/da active
- 2005-07-19 BR BRPI0514026-9A patent/BRPI0514026A/pt not_active Application Discontinuation
- 2005-07-19 EP EP05769486.1A patent/EP1773312B1/en active Active
-
2007
- 2007-01-08 IL IL180602A patent/IL180602A/en not_active IP Right Cessation
- 2007-03-01 ZA ZA200701816A patent/ZA200701816B/en unknown
- 2007-10-18 HK HK07111294.3A patent/HK1105871A1/xx not_active IP Right Cessation
-
2014
- 2014-07-16 CY CY20141100583T patent/CY1115416T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR101355122B1 (ko) | 2014-02-04 |
EA014444B1 (ru) | 2010-12-30 |
DK1773312T3 (da) | 2014-07-21 |
CA2573000A1 (en) | 2006-02-09 |
PL1773312T3 (pl) | 2014-09-30 |
BRPI0514026A (pt) | 2008-05-27 |
PT1773312E (pt) | 2014-07-25 |
US8853229B2 (en) | 2014-10-07 |
EP1773312B1 (en) | 2014-05-07 |
CN1993119A (zh) | 2007-07-04 |
WO2006013602A1 (en) | 2006-02-09 |
JP2008509132A (ja) | 2008-03-27 |
IL180602A0 (en) | 2008-03-20 |
ZA200701816B (en) | 2008-07-30 |
EP1773312A1 (en) | 2007-04-18 |
NZ552396A (en) | 2009-08-28 |
AU2005268402B2 (en) | 2010-08-26 |
IL180602A (en) | 2015-06-30 |
SI1773312T1 (sl) | 2014-08-29 |
EA200700240A1 (ru) | 2007-06-29 |
ES2481169T3 (es) | 2014-07-29 |
HK1105871A1 (en) | 2008-02-29 |
KR20070058460A (ko) | 2007-06-08 |
MX2007001009A (es) | 2007-04-16 |
CY1115416T1 (el) | 2017-01-04 |
CN1993119B (zh) | 2011-04-06 |
ITRM20040395A1 (it) | 2004-11-03 |
CA2573000C (en) | 2014-03-11 |
US20080089876A1 (en) | 2008-04-17 |
AU2005268402A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5103179B2 (ja) | スタチンおよびオメガ−3脂肪酸を含む組成物 | |
JP5474276B2 (ja) | 高脂血症治療剤 | |
US7195914B2 (en) | Composition and method for treatment of hypertriglyceridemia | |
KR101840082B1 (ko) | 지질 대사 장애의 치료에 유용한 조성물 | |
JP2004509143A (ja) | クロム錯体、共役脂肪酸及び/又は共役脂肪アルコールによる糖尿病の治療、体脂肪減少、インシュリン感受性の改善、高血糖症軽減及び高コレステロール血症軽減の方法及び組成物 | |
SK10802001A3 (sk) | Esenciálne mastné kyseliny na prevenciu kardiovaskulárnych príhod | |
MXPA04003233A (es) | Metodo y composicion para prevenir o reducir los sintomas del sindrome de resistencia a la insulina. | |
EP2007429A1 (en) | Oral formulation with beneficial cardiovascular effects, comprising berberine | |
JP2009525990A (ja) | 医薬組成物 | |
US6673773B2 (en) | Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent | |
US20170216237A1 (en) | Monounsaturated fatty acid compositions and use for treating atherosclerosis | |
JP5697337B2 (ja) | 2型糖尿病の処置に有用な組成物 | |
RU2387448C2 (ru) | Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью сердца или болезнью коронарной артерии | |
JP2002238499A (ja) | 高トリグリセリド血症治療剤 | |
JP2002241281A (ja) | 血中脂質改善剤組成物 | |
CA2551578A1 (en) | Lignan complex derived from flax seed used for treatment of hypercholesterolemic atherosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080716 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110712 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111011 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120731 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120904 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121001 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151005 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |